4-Pro-MET doesn't do anything on its own. It's a prodrug ? inactive until esterase enzymes in the body cleave its propionyloxy group and release 4-HO-MET (metocin), the serotonin receptor agonist that produces the actual effects. Same principle as psilocybin converting to psilocin, or 4-AcO-DMT converting to 4-HO-DMT. If you want to understand why 4-Pro-MET behaves the way it does ? onset, duration, dosing, stability ? the prodrug mechanism is where it starts.

A prodrug goes in inactive and gets activated inside the body. The strategy is more common than most people realize ? roughly 10% of all FDA-approved drugs are prodrugs: codeine (prodrug of morphine), valacyclovir (prodrug of acyclovir), levodopa (prodrug of dopamine). The payoffs include better chemical stability, improved oral bioavailability, slower release kinetics, and protection of sensitive functional groups during storage.

Nature got there first. Psilocybin is a phosphoryloxy prodrug of psilocin. Eat a psilocybin mushroom and alkaline phosphatase enzymes in the gut and liver strip the phosphate group away, yielding psilocin (4-HO-DMT), which crosses the blood-brain barrier and activates serotonin receptors. Synthetic chemists took the same logic and built acetyloxy (4-AcO) and propionyloxy (4-PrO) ester prodrugs of various 4-hydroxy tryptamines.

4-Pro-MET (4-Propionyloxy-N-methyl-N-ethyltryptamine, C₁₆H₂₂N₂O₂, MW 274.364 g/mol) carries a propionyloxy ester group (-O-CO-CH₂-CH₃) at position 4 of the indole ring ? essentially a chemical cap protecting the vulnerable 4-hydroxy site. Carboxylesterase enzymes, mainly CES1 and CES2 in the liver and intestinal wall, hydrolyze that ester bond.

The Hydrolysis Reaction

The conversion is textbook ester hydrolysis:

4-Pro-MET + H₂O ? 4-HO-MET + Propanoic Acid
(C₁₆H₂₂N₂O₂) ? (C₁₃H₁₈N₂O) + (C₃H₆O₂)

The esterase snaps the bond between the oxygen at position 4 and the carbonyl carbon of the propionate group. Water donates the hydroxyl that replaces the ester, regenerating 4-HO-MET's free 4-hydroxy group. The byproduct ? propanoic acid ? is a naturally occurring short-chain fatty acid the body handles routinely.

Mass Correction Factor

Here's the practical catch: about 20% of 4-Pro-MET's molecular weight is that propionyloxy group, and it gets stripped off before anything activates. So 20 mg of 4-Pro-MET delivers roughly 16 mg equivalent of active 4-HO-MET. When comparing doses across compounds, you have to account for that gap.

4-HO-MET's free hydroxyl group is unstable. Air, light, or moisture oxidizes it, producing dark degradation products and killing potency. Same reason psilocin mushrooms bruise blue ? it's the 4-hydroxytryptamine moiety oxidizing. Cap that group with a propionyloxy ester and the problems go away.

Enhanced Stability

The ester shield blocks oxidative degradation. Lab stability data show that ester prodrugs of 4-hydroxy tryptamines hold potency far longer than their free-hydroxyl counterparts at room temperature. The propionyloxy group (three carbons) offers more steric shielding than the acetyloxy group (two carbons), so 4-Pro-MET may edge out 4-AcO compounds on shelf life ? though no rigorous comparative study specific to 4-Pro-MET has been published yet.

Smoother Pharmacokinetics

Enzymatic hydrolysis is gradual. That means the active metabolite rises in plasma more slowly than it would from a direct 4-HO-MET dose. Community reports back this up ? they consistently describe the onset as "smoother" and "gentler" compared to 4-HO-MET, which is known for hitting fast and sometimes jarringly. The gentler curve may also explain 4-Pro-MET's longer total duration (5-8 vs. 4-6 hours).

Does 4-Pro-MET Have Its Own Receptor Activity?

Open question. Data from the related 4-PrO-DMT (Glatfelter et al. 2023) suggest the intact prodrug does have direct receptor binding ? 4-PrO-DMT showed a 5-HT2A functional EC50 of 3-93 nM in its ester form. If 4-Pro-MET behaves the same way, you'd get a mixed profile: partial direct activity during absorption, transitioning to full 4-HO-MET-mediated activity after hepatic conversion. We don't know yet.

4-HO-MET (4-Hydroxy-N-methyl-N-ethyltryptamine) ? metocin ? is what you actually get when 4-Pro-MET is hydrolyzed. Alexander Shulgin first synthesized it in the 1970s; it's entry #21 in TiHKAL (1997). As a non-selective serotonin receptor agonist, its binding affinities range from 4.0 nM to 950 nM across subtypes.

Shulgin called it "qualitatively a lot like psilocin" ? wave-like effects, altered color and form perception at 10-20 mg oral doses. Community reports agree on one distinction: 4-HO-MET tends to have a "clearer headspace" than psilocin, with stronger visual effects and less introspective weight. In vitro metabolic work has identified 12 metabolites using human liver microsomes, 4 of which have been confirmed in human urine. And one non-fatal case report documented a plasma concentration of 193 ng/mL during a 4-HO-MET-related clinical presentation.

What separates MET-series from DMT-series compounds? The nitrogen. MET carries an asymmetric N-methyl-N-ethyl substitution instead of the symmetric N,N-dimethyl of DMT. That asymmetry is thought to subtly shift receptor binding dynamics ? and it may be the reason MET and DMT compounds feel different.